메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

HCSA Community Services and Tan Tock Seng Hospital Sign MOU to Hepatitis C Elimination in Singapore

SINGAPORE, July 28, 2025 -- In celebration of the World Hepatitis Day (28 July), HCSA Community Services and Tan Tock Seng Hospital (TTSH), an anchor hospital of NHG Health, today signed a Memorandum of Understanding (MoU) to reinforce their shared commitment to eliminating Hepatitis C (HCV) among former drug offenders in Singapore, the World Health Organization's global strategy of eliminating Hepatitis C. This marks a significant step towards the Educate, Test, Treat! (ETT) initiative, launched in 2022 with the funding support of Gilead Sciences. Witnessed by Mdm Rahayu Mahza
- 김갑성 기자
- 2025-07-28 16:11
Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis

KOLKATA, India, July 28, 2025 -- In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was successfully treated with Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Manipal Hospital Dhakuria, under the expertise of Dr. Ashutosh Daga, Medical Oncologist, and Dr. Sagnik Ray, Surgical Oncologist. The 12-hour long procedure adds a milestone in cancer care treatment. The sexagenarian was initially taken to another hospital where she was misdiagnosed as a case of chronic liver failure with ascites
- 김갑성 기자
- 2025-07-28 15:20
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'

[ 메디채널 김갑성 기자 ] CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® biosimilar by Alteogen's license partner Qilu Pharmaceutical DAEJEON, South Korea, July 28, 2025 -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI® (code name: ALT-L9), a bi
- 김갑성 기자
- 2025-07-28 14:00
MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA'S FIRST MEDICAL TOURISM YEAR

KUALA LUMPUR, Malaysia, July 28, 2025 -- The Malaysia Healthcare Travel Council (MHTC) launched Malaysia Year of Medical Tourism (MYMT) 2026 at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health Malaysia, officiated the event, unveiling the campaign's logo and tagline, "Healing Meets Hospitality." MYMT 2026 aims to position Malaysia as a premier medical tourism destination by showcasing its advanced healthcare services and hospitality. The campaign also seeks to attract international heal
- 김갑성 기자
- 2025-07-28 12:17
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

HONG KONG, July 28, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). This submission represents the third accepted application for ivonescimab in China, following previous filings for its combination therapy in EGFR-TKI resistant locally advanced or metasta
- 김갑성 기자
- 2025-07-28 12:14
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

SHANGHAI and HONG KONG, July 28, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17t
- 김갑성 기자
- 2025-07-28 10:40
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug in China. XPOVIO® as a monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and in combination with dexamethasone in patients with R/R MM, two of the three approved indications of XPOVIO® in China, have already been included into China's National Reimbursement Drug List. Results from the BENCH
- 김갑성 기자
- 2025-07-28 10:35
Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous (SQ) depot formulation of small molecule GLP-1 receptor agonist ASC30. - Ultra-long-acting SQ depot formulation of small molecule ASC30 demonstrated a 36-day half-life in participants with obesity in the Phase Ib study, supporting once monthly administration. - Phase Ib study also demonstrated that compared to the trough concentration of ASC30 at Day 29, the ultra-long-acting SQ d
- 김갑성 기자
- 2025-07-28 08:15
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 28, 2025 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the six months ended June 30, 2025 (the "Reporting Period"). Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, total profit is expected to range between US$68 million (equivalent to approximately HK$53
- 김갑성 기자
- 2025-07-28 08:11
AESTURA, Korea's #1 Dermatologist-Recommended Dermocosmetic Brand Launches Exclusively at Sephora Australia

[ 메디채널 김갑성 기자 ] Premium dermocosmetic brand specialising in sensitive skin launches from August 26th, bringing clinically-proven innovation to Australian skincare market SYDNEY, July 28, 2025 -- AESTURA, Korea's #1 dermatologist-recommended dermocosmetic brand for sensitive skin[1], breaks new ground in the Australian skincare market with its exclusive launch at Sephora Australia stores and on Sephora.com.au, beginning August 26th, 2025. This strategic partnership with Sephora Australia answers the growing demand for advanced, science-backed solutions in the dermatologist skincare ca
- 김갑성 기자
- 2025-07-28 08:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-09-07_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 07일 19시 40분